Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
Status:
Completed
Trial end date:
2017-07-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see whether subjects with gout who receive febuxostat or
allopurinol for up to 9 years have a higher rate of serious heart and blood vessel
complications (major cardiovascular events).